Marginum Oy

28/10/2026

Marginum is pleased to join Neurocenter Finland in Helsinki on 5–6 November to celebrate five years of advancing collaboration in brain health.

The event will bring together researchers, healthcare professionals, patient organisations, policymakers and industry representatives to explore how collaboration can accelerate innovation and improve brain health outcomes.

Our CEO, Samu Lehtonen, will give a Trailblazer Talk on the journey from laboratory research to building a company around a medical innovation and on what it takes to bring an invention towards clinical practice.

We look forward to contributing to the discussion and connecting with colleagues across Finland’s brain health and innovation ecosystem.

15/10/2026

🇺🇸 Marginum has been granted a U.S. patent covering key aspects of its fluorescence detection technology underlying HIVEN®.

The patent strengthens our intellectual property portfolio and provides a strong foundation for the continued development and international commercialisation of HIVEN®, including future opportunities in the United States.

This milestone reflects our continued commitment to innovation in fluorescence-guided surgery and to developing technologies that integrate seamlessly into existing surgical workflows.

The United States Patent and Trademark Office (USPTO) has granted Marginum a patent covering key aspects of its fluorescence detection technology.

12/10/2026

Next stop: London!

We're heading to to connect with the UK neurosurgical community and continue the conversation around fluorescence-guided brain tumour surgery.

With growing clinical experience across Europe, we're looking forward to sharing the latest developments with HIVEN® and meeting colleagues in London.

Will you be attending? We'd love to connect!

London, UK | 12–16 October 2026 🇬🇧

🔗 Learn more about HIVEN®: https://www.marginum.com/en/solution

30/09/2026

Rome done. Hamburg next.

We’re at with HIVEN® set up and ready at booth #54.

Come see HIVEN® in action and discover a different approach to intraoperative fluorescence detection in the neurosurgical OR.

We’ll be here throughout EANS for demonstrations and conversations, so come by and meet the Marginum team.

📍 Hamburg, Germany | Booth #54 | 30 September – 4 October 🇩🇪

25/09/2026

We’re here at in Rome!

HIVEN® is set up and ready, and we’re looking forward to meeting the neuro-oncology community over the next few days.

Come by booth #8 to see HIVEN® in action, explore real-time fluorescence detection during 5-ALA-guided glioma surgery, and meet the Marginum team.

23/09/2026

Marginum is heading to in Hamburg. Have you met us yet?

We’re bringing a different approach to intraoperative fluorescence detection for the neurosurgical OR. HIVEN® analyses aspirated tissue during 5-ALA-guided surgery and turns fluorescence detection into near-real-time auditory feedback for the surgeon.

Come by booth #54 to see HIVEN® in action and meet the Marginum team.

📍Hamburg, Germany | 30 September–4 October 2026 🇩🇪

🔗 Learn more about HIVEN®: https://www.marginum.com/en/solution/

21/09/2026

Heading to in Rome? Let’s talk fluorescence-guided glioma surgery.

What happens to fluorescence information when the white light comes back on?

HIVEN® detects fluorescence from aspirated tissue during 5-ALA-guided glioma surgery and provides real-time auditory feedback, including when fluorescence is no longer visually apparent under white light.

Come see HIVEN® in action and meet the Marginum team at booth #8.
Rome, Italy | 24–27 September 2026 🇮🇹

Learn more about HIVEN®:
🔗 https://www.marginum.com/en/solution

27/08/2026

Marginum is proud to receive the 2026 Export2X Internationalisation Award 🏆

The recognition from Kuopion alueen kauppakamari highlights Marginum’s rapid international growth and the successful commercialisation of research-based medical technology.

Originating from internationally awarded research at Itä-Suomen yliopisto - University of Eastern Finland (UEF) and the Kuopio University Hospital Microsurgery Center, HIVEN® has advanced into a CE-marked medical device already used in the treatment of more than 100 patients worldwide, including in the United States.

We are grateful for this recognition of the work our team has done in Finland to bring new medical technology to international markets as we continue our global expansion. Thank you to the Kuopio Region Chamber of Commerce and to our partners for their continued support.

Marginum has received the 2026 Export2X Internationalisation Award, recognising its rapid growth and expansion into global markets.

11/08/2026

Marginum has entered a U.S. distribution partnership with ABS Med, Inc. 🇺🇸

Under the agreement, ABS Med will support the planned commercialisation and distribution of Marginum’s HIVEN® device across nine Midwestern states, subject to FDA authorisation.

With an established regional network and strong relationships with hospitals, surgical centres and operating-room teams, the company is well positioned to support the future introduction and clinical adoption of HIVEN®.

The partnership combines Marginum’s fluorescence-based tissue-monitoring technology with local market expertise and clinical support capabilities, establishing a strong foundation for U.S. market entry.

ABS Med has partnered with Marginum to support the planned distribution of HIVEN® across key Midwestern U.S. states, subject to FDA authorisation.

08/07/2026

Seeing what’s invisible in brain tumour surgery 🧠

We are pleased to share a recent article from the University of Illinois Chicago Department of Neurosurgery highlighting how 5-ALA is changing brain tumour surgery, and how HIVEN® by Marginum is being evaluated at UI Health in Chicago.

For neurosurgeons treating gliomas, one of the key challenges is distinguishing malignant tumour tissue from adjacent healthy brain tissue, particularly at the tumour margins. 5-ALA provides a fluorescent label for this demanding task. After administration, malignant tumour tissue glows under blue light, helping provide real-time definition of tumour margins.

HIVEN® provides an additional method for assessing 5-ALA fluorescence during surgery. As resected tissue passes through the device, HIVEN® detects fluorescence and provides the surgical team with audible feedback in near-real time, thereby supporting intraoperative assessment. As highlighted by Dr. Francesco Pucci, Assistant Professor and Neurosurgeon at the University of Illinois Chicago, the ongoing study represents an important step in evaluating how this technology may support surgical decision-making for patients with malignant glial brain tumours.

At Marginum Oy, we are grateful to the UI Health Neurosurgery team for their close collaboration in advancing this important clinical work.

Seeing What’s Invisible: How 5-ALA is Changing Brain Tumor Surgery Jonathan Miller | Posted on June 08, 2026 Introduction What if one of the biggest challenges in brain surgery is simply seeing what needs to be removed? For neurosurgeons treating brain tumors, that’s the reality. During surgery ...